Alam-Mehrjerdi Z, Abdollahi M, Higgs P, Dolan K. Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian J Psychiatr 2015; 16: 78-83.
Razzaghi EM, Rahimi Movaghar A, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J 2006; 3: 12.
Ministry of Health and Medical Education. Control of AIDS in the Islamic Republic of Iran's progress report [Online]. [cited 2013]; Available from: URL: http://www.unaids.org/sites/default/files/en/dataanalys is/knowyourresponse/countryprogressreport/2014cou ntries/IRN_narrative_report_2014_fa.pdf [In Persian].
Mohtasham AZ, Rezvani M, Jafari SR, Jafari SA. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 2007; 13(2): 250-6.
Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan- Iran. World J Gastroenterol 2005; 11(26): 4085-9.
Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pak J Med Sci 2007; 23(4): 510-3.
Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, et al. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 2013; 13(8): e12411.
Zobeiri M, Adibi P, Alavian SM. Intravenous drug use and hepatitis C virus in Iran. Hepat Mon 2012; 12(1): 9-10.
Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis 2010; 14(1): e28-e33.
Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, et al. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. J Viral Hepat 2013; 20(10): 708-14.
Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18(5): 359-63.
Alipour A, Haghdoost AA, Sajadi L, Zolala F. HIV prevalence and related risk behaviours among female partners of male injecting drugs users in Iran: results of a bio-behavioural survey, 2010. Sex Transm Infect 2013; 89(Suppl 3): iii41-iii44.
Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors correlated with hepatitis c and b virus infections among injecting drug users in Tehran, IR Iran. Hepat Mon 2012; 12(1): 23-31.
Bini EJ, Kritz S, Brown LS, Robinson J, Calsyn D, Alderson D, et al. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States. J Subst Abuse Treat 2012; 42(4): 438-45.
Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. J Hepatol 2009; 51(4): 628-31.
Reed C, Bliss C, Stuver SO, Heeren T, Tumilty S, Horsburgh CR Jr, et al. Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. Am J Public Health 2013; 103(1): 105-11.
Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD, et al. Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med 2014; 8(4): 249-57.
Orwat J, Samet JH, Tompkins CP, Cheng DM, Dentato MP, Saitz R. Factors associated with attendance in 12-step groups (Alcoholics Anonymous/Narcotics Anonymous) among adults with alcohol problems living with HIV/AIDS. Drug Alcohol Depend 2011; 113(2-3): 165-71.
Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol 2013; 11(8): 922-33.